BR0116507A - Fatores do crescimento de fibroblastos - Google Patents
Fatores do crescimento de fibroblastosInfo
- Publication number
- BR0116507A BR0116507A BR0116507-0A BR0116507A BR0116507A BR 0116507 A BR0116507 A BR 0116507A BR 0116507 A BR0116507 A BR 0116507A BR 0116507 A BR0116507 A BR 0116507A
- Authority
- BR
- Brazil
- Prior art keywords
- fgf
- cell
- fibroblast growth
- development
- differentiation
- Prior art date
Links
- 102000018233 Fibroblast Growth Factor Human genes 0.000 title abstract 5
- 108050007372 Fibroblast Growth Factor Proteins 0.000 title abstract 5
- 229940126864 fibroblast growth factor Drugs 0.000 abstract 3
- 230000004663 cell proliferation Effects 0.000 abstract 2
- 102000039446 nucleic acids Human genes 0.000 abstract 2
- 108020004707 nucleic acids Proteins 0.000 abstract 2
- 150000007523 nucleic acids Chemical group 0.000 abstract 2
- 229920001184 polypeptide Chemical group 0.000 abstract 2
- 108090000765 processed proteins & peptides Chemical group 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 208000005623 Carcinogenesis Diseases 0.000 abstract 1
- 108090000569 Fibroblast Growth Factor-23 Proteins 0.000 abstract 1
- 108050002085 Fibroblast growth factor 20 Proteins 0.000 abstract 1
- 102100031361 Fibroblast growth factor 20 Human genes 0.000 abstract 1
- 102100024802 Fibroblast growth factor 23 Human genes 0.000 abstract 1
- 230000019552 anatomical structure morphogenesis Effects 0.000 abstract 1
- 230000033115 angiogenesis Effects 0.000 abstract 1
- 230000027455 binding Effects 0.000 abstract 1
- 230000004071 biological effect Effects 0.000 abstract 1
- 230000036952 cancer formation Effects 0.000 abstract 1
- 231100000504 carcinogenesis Toxicity 0.000 abstract 1
- 230000024245 cell differentiation Effects 0.000 abstract 1
- 230000018109 developmental process Effects 0.000 abstract 1
- 230000004069 differentiation Effects 0.000 abstract 1
- 230000013020 embryo development Effects 0.000 abstract 1
- 210000002950 fibroblast Anatomy 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 230000006698 induction Effects 0.000 abstract 1
- 210000005036 nerve Anatomy 0.000 abstract 1
- 210000004498 neuroglial cell Anatomy 0.000 abstract 1
- 210000002569 neuron Anatomy 0.000 abstract 1
- 230000014511 neuron projection development Effects 0.000 abstract 1
- 230000003961 neuronal insult Effects 0.000 abstract 1
- 230000006576 neuronal survival Effects 0.000 abstract 1
- 210000004248 oligodendroglia Anatomy 0.000 abstract 1
- 230000017956 positive regulation of myelination Effects 0.000 abstract 1
- 230000035755 proliferation Effects 0.000 abstract 1
- 230000001737 promoting effect Effects 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 238000011084 recovery Methods 0.000 abstract 1
- 210000004116 schwann cell Anatomy 0.000 abstract 1
- 230000011664 signaling Effects 0.000 abstract 1
- 210000000130 stem cell Anatomy 0.000 abstract 1
- 230000004936 stimulating effect Effects 0.000 abstract 1
- 230000000638 stimulation Effects 0.000 abstract 1
- 230000029663 wound healing Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1825—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/50—Fibroblast growth factor [FGF]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Transplantation (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
"FATORES DO CRESCIMENTO DE FIBROBLASTOS". Foram identificados novos ácidos nucléicos, seq³ências de polpeptídeos, e seus reguladores de ácido nucléico que codificam um fator de crescimento de fibroblastos (FGF) , preferivelmente FGF-20 ou FGF-23, uma classe de polipeptídeos envolvidos no desenvolvimento, diferenciação e morfogênese, por exemplo, na sinalização de célula a célula e na proliferação de células. Um FGF da presente invenção, seus fragmentos e seus derivados, têm uma ou mais das seguintes atividades biológicas, por exemplo, a promoção da cura de feridas; a promoção da sobrevivência neuronal; o estímulo da proliferação de células, por exemplo, a proliferação de células tronco, fibroblastos, neurónios, glia, oligodendrócitos, células de Schwann, ou seus progenitores; a diferenciação da modulação de células; a indução do desenvolvimento embriónico; o estímulo do desenvolvimento de neuritos; a intensificação da recuperação de nervos ou danos neuronais; o estímulo da mielinação; o estímulo de angiogênese; a atividade de ligação de receptor; a modulação da tumorigênese, etc.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US25183700P | 2000-12-08 | 2000-12-08 | |
US10/005,646 US20020151496A1 (en) | 2000-12-08 | 2001-12-07 | Novel fibroblast growth factors |
PCT/US2001/047350 WO2002046424A2 (en) | 2000-12-08 | 2001-12-10 | Fibroblast growth factors |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0116507A true BR0116507A (pt) | 2004-01-06 |
Family
ID=26674594
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0116507-0A BR0116507A (pt) | 2000-12-08 | 2001-12-10 | Fatores do crescimento de fibroblastos |
Country Status (21)
Country | Link |
---|---|
US (2) | US20020151496A1 (pt) |
EP (1) | EP1389237A2 (pt) |
JP (1) | JP2005506275A (pt) |
KR (1) | KR20040052442A (pt) |
CN (1) | CN1518597A (pt) |
AU (1) | AU2603402A (pt) |
BG (1) | BG107888A (pt) |
BR (1) | BR0116507A (pt) |
CA (1) | CA2431374A1 (pt) |
CZ (1) | CZ20031570A3 (pt) |
EE (1) | EE200300269A (pt) |
HU (1) | HUP0400657A1 (pt) |
IL (1) | IL156259A0 (pt) |
MX (1) | MXPA03005142A (pt) |
NO (1) | NO20032573L (pt) |
PL (1) | PL366158A1 (pt) |
RU (1) | RU2329058C2 (pt) |
SI (1) | SI21372A (pt) |
SK (1) | SK7012003A3 (pt) |
WO (1) | WO2002046424A2 (pt) |
ZA (1) | ZA200305236B (pt) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7253266B2 (en) | 1999-07-27 | 2007-08-07 | Curagen Corporation | Polypeptides of FGF-CX |
US6982250B2 (en) | 2000-11-06 | 2006-01-03 | Curagen Corporation | Methods of prevention and treatment of inflammatory bowel disease |
US7189693B2 (en) | 2000-11-06 | 2007-03-13 | Curagen Corporation | Treatment of inflammatory bowel disease using fibroblast growth factor CX polypeptides |
CA2468610A1 (en) * | 2002-01-15 | 2003-07-24 | Eli Lilly And Company | Method for reducing morbidity and mortality in critically ill patients |
EP2335738A1 (en) * | 2003-04-01 | 2011-06-22 | United States Government as represented by the Department of Veteran's Affaires | Stem-cell, precursor cell or target cell-based treatment of wound healing |
WO2004105787A1 (en) * | 2003-05-28 | 2004-12-09 | The University Of Kyoto | Methods of using combinations of egf-2 and egf-20 to treat central nervous system disorders |
PT2726511T (pt) | 2011-07-01 | 2019-10-14 | Ngm Biopharmaceuticals Inc | Composições, usos e métodos para o tratamento de distúrbios e doenças metabólicas |
EP3798228A1 (en) | 2012-11-28 | 2021-03-31 | NGM Biopharmaceuticals, Inc. | Compositions and methods for treatment of metabolic disorders and diseases |
US9290557B2 (en) | 2012-11-28 | 2016-03-22 | Ngm Biopharmaceuticals, Inc. | Compositions comprising variants and fusions of FGF19 polypeptides |
CN108888757A (zh) | 2012-12-27 | 2018-11-27 | 恩格姆生物制药公司 | 用于调节胆汁酸体内稳态及治疗胆汁酸紊乱和疾病的方法 |
US9273107B2 (en) | 2012-12-27 | 2016-03-01 | Ngm Biopharmaceuticals, Inc. | Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
BR112016009099A2 (pt) | 2013-10-28 | 2017-09-19 | Ngm Biopharmaceuticals Inc | Método para determinar se um indivíduo de teste tendo um distúrbio metabólico é um candidato para o tratamento com uma variante de fgf19, método para determinar se uma variante de fgf19 é um candidato para tratar um indivíduo de teste, uso de uma variante fgf19, modelo para determinar se uma variante de fgf19 é um candidato para prevenir uma doença |
KR102489475B1 (ko) | 2014-01-24 | 2023-01-20 | 엔지엠 바이오파마슈티컬스, 아이엔씨. | 결합 단백질 및 그의 사용 방법 |
WO2015183890A2 (en) | 2014-05-28 | 2015-12-03 | Ngm Biopharmaceuticals, Inc. | Methods and compositions for the treatment of metabolic disorders and diseases |
US10456449B2 (en) | 2014-06-16 | 2019-10-29 | Ngm Biopharmaceuticals, Inc. | Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
UA123763C2 (uk) | 2014-10-23 | 2021-06-02 | Енджіем Байофармасьютикалз, Інк. | Фармацевтична композиція для контролю або лікування захворювання або порушення, пов’язаного з fgf19 |
WO2016073855A1 (en) | 2014-11-07 | 2016-05-12 | Ngm Biopharmaceuticals, Inc. | Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders |
US10800843B2 (en) | 2015-07-29 | 2020-10-13 | Ngm Biopharmaceuticals, Inc. | Beta klotho-binding proteins |
AU2016353988B2 (en) | 2015-11-09 | 2019-09-26 | Ngm Biopharmaceuticals, Inc. | Methods for treatment of bile acid-related disorders |
EP3503882A4 (en) | 2016-08-26 | 2020-07-29 | NGM Biopharmaceuticals, Inc. | METHOD FOR TREATING FIBROBLAST GROWTH FACTOR-19-MEDIATED CARCINOMAS AND TUMORS |
CN107050428B (zh) * | 2017-03-23 | 2020-05-05 | 温州医科大学 | Fgf20药物及其对脑创伤的治疗应用 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000060085A1 (en) * | 1999-04-02 | 2000-10-12 | Millennium Pharmaceuticals, Inc. | Fibroblast growth factor-20 |
EP1224283A2 (en) * | 1999-10-22 | 2002-07-24 | Chiron Corporation | Human and rat fgf-20 genes and gene expression products |
ES2335386T3 (es) * | 1999-11-18 | 2010-03-26 | Novartis Vaccines And Diagnostics, Inc. | Gen fgf-21 humano y productos de expresion genica. |
AU2001262934A1 (en) * | 2000-06-01 | 2001-12-11 | Eli Lilly And Company | Human fgf-20 nucleic acids and polypeptides |
AU2001271811B2 (en) * | 2000-07-03 | 2006-07-20 | Curagen Corporation | Novel fibroblast growth factors and nucleic acids encoding same |
-
2001
- 2001-12-07 US US10/005,646 patent/US20020151496A1/en not_active Abandoned
- 2001-12-10 HU HU0400657A patent/HUP0400657A1/hu unknown
- 2001-12-10 SK SK701-2003A patent/SK7012003A3/sk unknown
- 2001-12-10 BR BR0116507-0A patent/BR0116507A/pt not_active IP Right Cessation
- 2001-12-10 EE EEP200300269A patent/EE200300269A/xx unknown
- 2001-12-10 CN CNA018202993A patent/CN1518597A/zh active Pending
- 2001-12-10 IL IL15625901A patent/IL156259A0/xx unknown
- 2001-12-10 CA CA002431374A patent/CA2431374A1/en not_active Abandoned
- 2001-12-10 RU RU2003119657/14A patent/RU2329058C2/ru not_active IP Right Cessation
- 2001-12-10 CZ CZ20031570A patent/CZ20031570A3/cs unknown
- 2001-12-10 WO PCT/US2001/047350 patent/WO2002046424A2/en active IP Right Grant
- 2001-12-10 AU AU2603402A patent/AU2603402A/xx active Pending
- 2001-12-10 JP JP2002548141A patent/JP2005506275A/ja active Pending
- 2001-12-10 MX MXPA03005142A patent/MXPA03005142A/es not_active Application Discontinuation
- 2001-12-10 EP EP01995460A patent/EP1389237A2/en active Pending
- 2001-12-10 SI SI200120066A patent/SI21372A/sl not_active IP Right Cessation
- 2001-12-10 PL PL01366158A patent/PL366158A1/xx not_active Application Discontinuation
- 2001-12-10 KR KR10-2003-7007614A patent/KR20040052442A/ko not_active Application Discontinuation
-
2003
- 2003-06-06 BG BG107888A patent/BG107888A/bg unknown
- 2003-06-06 NO NO20032573A patent/NO20032573L/no not_active Application Discontinuation
- 2003-07-07 ZA ZA2003/05236A patent/ZA200305236B/en unknown
-
2007
- 2007-06-22 US US11/821,191 patent/US20080057076A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
IL156259A0 (en) | 2004-01-04 |
WO2002046424A2 (en) | 2002-06-13 |
NO20032573L (no) | 2003-07-22 |
AU2002226034A2 (en) | 2002-06-18 |
CZ20031570A3 (cs) | 2004-01-14 |
RU2329058C2 (ru) | 2008-07-20 |
US20080057076A1 (en) | 2008-03-06 |
ZA200305236B (en) | 2005-06-29 |
SK7012003A3 (en) | 2004-04-06 |
BG107888A (bg) | 2004-08-31 |
AU2603402A (en) | 2002-06-18 |
US20020151496A1 (en) | 2002-10-17 |
RU2003119657A (ru) | 2005-02-27 |
EE200300269A (et) | 2003-10-15 |
EP1389237A2 (en) | 2004-02-18 |
HUP0400657A1 (en) | 2006-04-28 |
PL366158A1 (en) | 2005-01-24 |
NO20032573D0 (no) | 2003-06-06 |
SI21372A (sl) | 2004-06-30 |
WO2002046424A3 (en) | 2003-11-27 |
JP2005506275A (ja) | 2005-03-03 |
CN1518597A (zh) | 2004-08-04 |
CA2431374A1 (en) | 2002-06-13 |
KR20040052442A (ko) | 2004-06-23 |
MXPA03005142A (es) | 2004-10-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0116507A (pt) | Fatores do crescimento de fibroblastos | |
Sendtner et al. | Effect of ciliary neurotrophic factor (CNTF) on motoneuron survival | |
Azmitia et al. | S-100B but not NGF, EGF, insulin or calmodulin is a CNS serotonergic growth factor | |
Zhou et al. | Endogenous brain-derived neurotrophic factor is anterogradely transported in primary sensory neurons | |
Cheng et al. | NT-3 and BDNF protect CNS neurons against metabolic/excitotoxic insults | |
Cordeiro et al. | Acidic fibroblast growth factor enhances peripheral nerve regeneration in vivo | |
Wong et al. | The neurotrophins BDNF, NT‐3 and NT‐4/5, but not NGF, up‐regulate the cholinergic phenotype of developing motor neurons | |
AU716811B2 (en) | Regulation of neural stem cell proliferation | |
Vaccarino et al. | 6 Fibroblast Growth Factor Signaling Regulates Growth and Morphogenesis at Multiple Steps during Brain Development | |
Asaumi et al. | Expression of neurotrophins and their receptors (TRK) during fracture healing | |
Wright et al. | Neurotrophic factors promote the maturation of developing sensory neurons before they become dependent on these factors for survival | |
Yin et al. | Cell death of spinal motoneurons in the chick embryo following deafferentation: rescue effects of tissue extracts, soluble proteins, and neurotrophic agents | |
Knusel et al. | Brain-derived neurotrophic factor administration protects basal forebrain cholinergic but not nigral dopaminergic neurons from degenerative changes after axotomy in the adult rat brain | |
Numan et al. | Expression of trkB and trkC mRNAs by adult midbrain dopamine neurons: a double‐label in situ hybridization study | |
US5349056A (en) | Modified ciliary neurotrophic factors | |
Lärkfors et al. | Characterization of the responses of Purkinje cells to neurotrophin treatment | |
Sensenbrenner | The neurotrophic activity of fibroblast growth factors | |
Crutcher et al. | Entorhinal lesions result in increased nerved growth factor-like growth-promoting activity in medium conditioned by hippocampal slices | |
Enokido et al. | Basic fibroblast growth factor rescues CNS neurons from cell death caused by high oxygen atmosphere in culture | |
Oppenheim | The concept of uptake and retrograde transport of neurotrophic molecules during development: history and present status | |
Albert et al. | Stimulation in cell culture of mesenchymal cells of newt limb blastemas by EDGF I or II (basic or acidic FGF) | |
Gladwin et al. | Olfactory ensheathing cells: part I—current concepts and experimental laboratory models | |
Cuevas et al. | Acidic fibroblast growth factor prevents post-axotomy neuronal death of the newborn rat facial nerve | |
Blottner et al. | TGF‐β rescues target‐deprived preganglionic sympathetic neurons in the spinal cord | |
Grothe et al. | Effects of basic fibroblast growth factor on survival and choline acetyltransferase development of spinal cord neurons |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 8A E 9A ANUIDADE(S). |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2112 DE 28/06/2011. |